Oxygent perflubron: Phase IIb discontinued

ALLP discontinued a double-blind, placebo-controlled, dose-escalation, French Phase IIb trial in 128 patients in order to focus on developing Oxygent in China. Beijing Double-Crane Pharmaceutical Co....